Date: 29 Aug 2012
Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: This study aimed too compare the pharmacokinetic and pharmacodynamic profile of intermittent and continuously infused ceftazidime in patients with nosocomial pneumonia.
Design and Setting: Prospective, randomised study set in a large community-teaching hospital.
Interventions: Thirty-four patients receiving ceftazidime either as an intermittent infusion or a continuous infusion underwent blood sampling for drug concentration determinations between days 2 to 5 of therapy. In addition, at study enrolment sputum samples were obtained for Gram’s stain and culture. The minimum inhibitory concentration (MIC) of isolated organisms to ceftazidime was determined using the broth microdilution technique.
Main Outcome Measures: Pharmacokinetic parameters were derived individually for each patient. The pharmacodynamic profile of ceftazidime was assessed as the duration of time the serum concentration remained above the MIC (T > MIC) of the organism(s) for each regimen.
Results: Patients were well matched for demographic variables. The pharmacokinetic parameter estimates (mean ± SD) for patients receiving the intermittent infusion therapy were as follows: maximum concentration in serum 106.5 ± 34.6 mg/L; half-life 3.2 ± 2.5 hours; total body clearance (CLt) 142.5 ± 59 ml/min. The steady-state concentration with the continuous infusion regimen was 17.4 ± 6.1 mg/L, while the CLt was similar at 133.2 ± 37 ml/min. Forty-six pathogens were isolated in 27 patients. The continuous infusion regimen maximised the pharmacodynamics of ceftazidime as T > MIC was 100% of the dosage interval in all patients, whereas the intermittent infusion regimens resulted in T > MIC values of 56 to 100%.
Conclusions: In critically ill patients with nosocomial pneumonia the administration of ceftazidime by continuous infusion appears to optimise the pharmacodynamic profile of this β-lactam by constantly providing concentrations in excess of the MIC of susceptible organisms over the course of therapy.
Nicolau DP, Lacy MK, McNabb JC, et al. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Prac 1999; 8: 45–9CrossRef
Nicolau DP, Nightingale CH, Banevicius MA, et al. Ceftazidime serum bactericidal activity: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40: 61–4PubMed
National Committee for Clinical Laboratory Standards: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard. NCCLS document M7-A4. Wayne, National Committee for Clinical Laboratory Standards, 1997
Vondracek TG. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 1995; 29: 415–24PubMed
Zeisler JA, McCarthy JD, Richelieu WA, et al. Cefuroxime by continuous infusion: a new standard of care? Infect Med 1992; 11:54–60
Ambrose PG, Quintiliani R, Nightingale CH, et al. Continuous versus intermittent infusion of cefuroxime for the therapy of community-acquired pneumonia. Infect Dis Clin Prac 1998; 7: 463–70CrossRef
Houlihan HH, Mercier RC, McKinnon PS, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with Gram-negative infection. [abstract No. A-42). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Octl: Toronto, Ontario, Canada
Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996; 40: 691–5PubMed
Castela N, Taburet AM, Carlet J, et al. Pharmacokinetics of ceftazidime during continuous infusion in intensive care patients [abstract No. A11]. Program Abstracts 34th Inter-science Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7: Orlando, Florida
National Committee for Clinical and Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Eighth informational supplement. NCCLS document M100-S8. Wayne, PA. 1998
- Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia
Clinical Drug Investigation
Volume 18, Issue 2 , pp 133-139
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Author Affiliations
- 1. Division of Infectious Diseases, Hartford Hospital, 80 Seymour Street, Hartford, Connecticut, 06102, USA
- 2. University of Kansas Medical Center, Kansas City, Kansas, USA